Chronological ageing is a biological process that results in accumulated cellular damage, ultimately driving the onset of metabolic disfunction. We aim to develop new therapeutic approaches to these ageing-associated diseases, by targeting metabolism in cancer stem cells (CSCs) and senescent fibroblasts. More specifically, we will screen a series of chemical libraries containing FDA-approved drugs, natural products, and novel chemical entities, to identify compounds that can effectively age-associated metabolic features. Through this screening and validation approach, we will identify compounds that preferentially kill CSCs and senescent fibroblasts, using established cell lines.

This position will involve the screening and discovery of drugs that target the metabolic phenotype of senescent cells and cancer stem cells, across multiple cancer types.

The purpose of this role is to support Lunella Biotech’s mission in the discovery of anti-ageing and anti-cancer therap...